Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The management estimates the cost of capital for a project of this risk level to be 8.5%. The corporate tax rate is 28%. What are the annual after-tax cash flows?

Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The management estimates the cost of capital for a project of this risk level to be 8.5%. The corporate tax rate is 28%. What are the annual after-tax cash flows?

Corporate Fin Focused Approach

5th Edition

ISBN:9781285660516

Author:EHRHARDT

Publisher:EHRHARDT

Chapter11: Cash Flow Estimation And Risk Analysis

Section: Chapter Questions

Problem 16P

See similar textbooks

Similar questions

Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Rachel Duncan is the CEO of Dyad Pharmaceuticals, and she faces a decision about her company's newest and most promising drug candidate: NZT-48. Clinical trials have been completed, and the team awaits an approval decision from the U.S. Food and Drug Administration (FDA) before it can be marketed. In the meantime, Ms. Duncan receives an offer from a global biotech company, International Genetics Incorporated (InGen) to license NZT-48 from Dyad. (Licensing here means that InGen provides capital to help the development and launch process of the new drug, but will share the profits with Dyad once the drug enters the market.) With InGen's offer, Ms. Duncan has a decision to make right now, before the FDA's decision. She can accept InGen's offer. If FDA approves the new drug, then Ms. Duncan estimates that her company's valuation will reach $3 billion; if FDA does not approve, with InGen's injected capital, Ms. Duncan estimates that her company would still value at $1 billion. If Ms. Duncan…
Gramax Health Bhd (GHB), a company operates in a health industry, is working in a project to develop a test kit that is able to determine the level of immunity a person has towards Covid- 19 based on his or her antibodies with higher accuracy rate compared with other similar test kits that are available in the market. In a recent business combination, GHB acquires a research and development (R&D) project of Vital Life Bad (VLB) to develop a similar test kit with the one it develops. GHB does not intend to complete the project that had been acquired as it would compete with its own project. Its main intention to acquire the project is to prevent its competitors from obtaining access to the technology. Meanwhile, as part of its effort to fund its R&D projects, on 31 December 2019 GHB issued at par in a private placement a RM3 million 5-year fixed rate bond with an annual 10% interest coupon rate. On 31 December 2020, GHB's credit spread has deteriorated due to a change in its…
Al Omani, an SAOC company based in Muscat specializing in the manufacture and distribution equipment for disabled people, and their major clients are ministry of health and various private hospitals in Oman. Currently the company is evaluating a new capital expenditure project. In a joint venture with a German based company, it has developed a remote controlled pushchair, one of the first of its kind on the market. It has been unable to obtain a patent for the invention, but the management is sure that it will capture the market for the first three years. However year 4 and 5 it expects to be faced with firm competition. The details are set out below. (1) The project has an immediate cost of 2, 100, 000 . () Sales are expected to be RO.1,550,000 per annum for years 1 to 3, falling to RO.650,000 per annum for the two years after that No further sales of the product are expected after the end of this five-year period. (3) Cost of sales is 40% of sales. (4) Distribution costs represent…
Khair Ltd carries out research and development on a continuousbasis. The directors of the company are passionate aboutimproving their medicinal drugs and finding new cures.In the current financial year, the company has been makingsignificant findings regarding a vaccine for the coronavirus. To thiseffect, they have registered a patent for a new vaccine that willsoon be available to customers. The following costs have beenincurred in respect of the patent in the current financial year.Research salaries R250 000Development salaries R450 000Initial marketing costs R30 000Fees to register patent R78 000Materials used in development R12 000The development was completed on 1 July 2020.Patents are amortised on a straight‐line basis at 20% per annumwith no residual value.Prepare the journal entry to recognise the patent in the financialstatements of Khair Ltd on 1 July 2020.Narrations are required
AsiaChem is a pharmaceutical company in Asia. The company’s research department has identified a compound that can cure a common cold without any side effects. Unfortunately, the manufacture of this compound requires the company to invest heavily in a high technology factory which will use a number of new techniques, some of which are unproven. The company will also need to recruit and retain the services of a number of eminent scientists, each of whom is both vital to the project and would be irreplaceable. Financing this project will require the company to borrow heavily. The company is unlikely to survive as an independent entity if it invests in this project and it fails. The directors have been advised that there is at least a 50% chance of a catastrophic failure. The project has a beta of 0.5. The risk free rate is 3% and the equity risk premium is 8%. The project offers an estimated return of 24%. Required: I. Calculate the required rate of return for the project. II.…
Tommy Gunn is a division manager for K-Cern Inc., a small pharmaceutical company. Tommy's division has been working on a new drug that has the potential to revolutionize the treatment of skin cancer. Once the drug is proven to be effective in clinical trials, it will be approved for sale by the government and patented by the company. Because of the potential market for this drug, it is highly likely that the company's revenues and net income will increase significantly when it is approved. Tommy recently saw an internal company memo indicating that the drug passed its final clinical trial and that the company has received government approval to sell the drug. The company will issue a press release announcing this news in the next two days, and this announcement is expected to result in a dramatic increase in the company's stock price. Tommy knows that there is “free money” to be made if he invests in the stock before the announcement is made. However, K-Cern has a strict policy against…
Tommy Gunn is a division manager for K-Cern Inc., a small pharmaceutical company. Tommy's division has been working on a new drug that has the potential to revolutionize the treatment of skin cancer. Once the drug is proven to be effective in clinical trials, it will be approved for sale by the government and patented by the company. Because of the potential market for this drug, it is highly likely that the company's revenues and net income will increase significantly when it is approved. Tommy recently saw an internal company memo indicating that the drug passed its final clinical trial and that the company has received government approval to sell the drug. The company will issue a press release announcing this news in the next two days, and this announcement is expected to result in a dramatic increase in the company's stock price. Tommy knows that there is “free money” to be made if he invests in the stock before the announcement is made. However, K-Cern has a strict policy against…
. Refresh Resorts, Inc., operates health spas in Key West, Florida; Phoenix, Arizona; and Carmel, California. The Key West spa was the company’s first and opened in 1991. The Phoenix spa opened in 2004, and the Carmel spa opened in 2013. Refresh Resorts has previously evaluated divisions based on RI, but the company is considering changing to an EVA approach. All spas are assumed to face similar risks. Data for 2017 are: Q. Why might Refresh Resorts want to use EVA instead of RI for evaluating the performance of the three spas?
. Refresh Resorts, Inc., operates health spas in Key West, Florida; Phoenix, Arizona; and Carmel, California. The Key West spa was the company’s first and opened in 1991. The Phoenix spa opened in 2004, and the Carmel spa opened in 2013. Refresh Resorts has previously evaluated divisions based on RI, but the company is considering changing to an EVA approach. All spas are assumed to face similar risks. Data for 2017 are: Q.How does the selection of asset measurement method affect goal congruence?